re: Ann: Mix and Go at Emerging Technology Co... A royalties biased deal would highlight Management's expectation of market penetration IMHO. However eBio would have attempt to negotiate for whats best for their books too, but on a long term deal mutual benefit is the go. I'm not putting too much weight on the details of this particular deal. Look so many things, for and against, could be read into whatever the deal outcome. e.g. On the same terms it could be argued - Is it a deal at premium for market signal, OR a deal at discount for early adoption? Whatever it is, it is only the forth deal - the measure will be the sum of the basket of deals Management can secure.
NB: I see the latest preso notes Life Technology's TO of eBioscience. Acknowledgement and/or highlight?
Ann: Mix and Go at Emerging Technology Conference, page-38
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.9¢ |
Change
0.003(11.5%) |
Mkt cap ! $72.20M | |||
| Open | High | Low | Value | Volume |
| 3.1¢ | 3.7¢ | 2.9¢ | $1.433M | 44.19M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 870964 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 511263 | 4 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ADO (ASX) Chart |